MedTrace Logo

Nevirapine Dosing in Neonates for Prophylaxis of Mother-to-Child-Transmission (MTCT) of HIV Infection

NCT02166502 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 27

Last updated 2015-11-18

No results posted yet for this study

Summary

The purpose of this study is to determine whether the current dose of nevirapine recommended in the Ontario Ministry of Health vertical transmission prevention protocol achieves therapeutic drug levels in newborn infants at high risk of HIV infection.

Conditions

  • Human Immunodeficiency Virus
  • HIV
  • Vertical Infection Transmission

Sponsors & Collaborators

  • Canadian Foundation for AIDS Research (CANFAR)

    collaborator OTHER

  • Children's Hospital of Eastern Ontario

    collaborator OTHER

  • Unity Health Toronto

    collaborator OTHER

  • Mount Sinai Hospital, Canada

    collaborator OTHER

  • The Hospital for Sick Children

    lead OTHER

Principal Investigators

  • Ari Bitnun, MD · The Hospital for Sick Children

Eligibility

Max Age
72 Hours
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2015-05-31
Completion
2015-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02166502 on ClinicalTrials.gov